Monte Rosa Therapeutics Inc (GLUE) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $18.50
• Market Cap: $1.38B
• P/E Ratio: 56.53
• EPS: $0.32
• 52-Week High: $25.77
• 52-Week Low: $3.50

Market Sentiment

Monte Rosa Therapeutics Inc currently has a Bullish sentiment score of 0.37.

About Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics, Inc. (GLUE) is a cutting-edge biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to developing precision small molecule therapeutics that exploit the body’s innate mechanisms for targeted protein degradation. The company's proprietary technology platforms enable it to tackle significant unmet medical needs in various fields, particularly in cancer and autoimmune disorders. With a promising pipeline of candidates and a strong commitment to scie...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Monte Rosa Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does GLUE pay dividends?

Monte Rosa Therapeutics Inc (GLUE) does not currently pay a regular dividend.

What is GLUE's P/E ratio?

Monte Rosa Therapeutics Inc has a price-to-earnings (P/E) ratio of 56.53.

What is GLUE's market cap?

Monte Rosa Therapeutics Inc (GLUE) has a market capitalization of $1.38B with a current stock price of $18.50.